The prevalence, mortality, and cost of heart failure (HF) is substantial and the gaps in care are alarming. Over the past five years, the treatment landscape for HF has evolved significantly, with exponential growth in clinical trials and therapeutic options.

The ACC's Heart Failure and SGLT2is: The New Pillar in Care initiative is designed to provide practical guidance for cardiologists on the implementation of sodium glucose cotransporter 2 inhibitors (SGLT2is) into treatment of patients with heart failure.

Use the navigation buttons below to explore educational tools and resources focusing on patient selection, dosing, and timing, among other clinical considerations to improve outcomes for HF patients.

This initiative is supported by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company, LLC.